Access to Novel, High-Cost Cancer Medicines2019-03-29T19:28:00+00:00

 

Access to Novel, High-Cost Cancer Medicines – Towards a More Holistic Approach to Realising Universal Health Coverage

Providing access to novel, high-cost cancer medicines poses ethical challenges in all health systems.  In this presentation, I will discuss how existing ethical frameworks may be augmented to help policy-makers define approaches for providing access to expensive innovative cancer therapies, in the face of multiple unmet health care needs and constrained resources. An objective of the presentation is to invigorate and sustain ongoing conversations on evidence and broader value-based considerations needed to inform ethical decisions on high-cost medicines.

Faculty:

Calvin Ho, JSD, LLM, M.Sc.Assistant Professor at the Centre for Biomedical Ethics at Yong Loo Lin School of Medicine, National University of Singapore